コレステロールと冠動脈の1世紀:プラークから遺伝子,スタチンまで
Joseph L Goldstein1, Michael S Brown1
1Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cell
|March 28, 2015
まとめ
低密度リポプロテイン (LDL) コレステロールの低下は,冠動脈疾患による死亡の予防に不可欠です. 誰が,いつ,いつまでLDLコレステロールを治療すべきかを理解することは,心臓病を排除する鍵です.
科学分野:
- 心血管科学 心血管科学
- メタボリック研究
- 遺伝学 遺伝学とは
背景:
- 冠動脈性心疾患 (CHD) は,工業国における死亡の大きな部分を占めています.
- 低密度脂質タンパク質 (LDL) コレステロールは,心臓病の主な原因因子として特定されています.
- 肝臓のLDL受容体 (LDLRs) は,血液中のLDLレベルを調節する上で重要な役割を果たします.
研究 の 目的:
- 心血管疾患の排除の主要な目標として,LDLコレステロールの低下の重要性を強調する.
- LDLの減少のための効果的な方法の可用性を強調する.
- LDL治療に関する重要な臨床的問題を特定するために:患者の選択,タイミング,および持続時間.
主な方法:
- この研究は,LDLコレステロールとその心臓病における役割に関する既存の研究をレビューしたものです.
- LDLR機能,LDLレベル,および心血管疾患の関係に関する分析.
- 超脂血症の治療決定に影響を与える重要な要因の特定.
主要な成果:
- LDLR機能を損なう変異は,LDLの上昇と早期発症の心臓発作につながる.
- 改善されたLDLR機能は,LDLのレベルを低下させ,心臓発作の発生率を低下させます.
- 現在,LDLコレステロールを下げるための効果的な介入方法があります.
結論:
- LDLコレステロールの低下は,CHDの予防と排除の主要な戦略です.
- 最適な患者管理戦略に取り組むために,さらなる研究と臨床ガイドラインが必要です.
- 誰を治療すべきか,いつ治療すべきか,どのくらいの期間を治療すべきかといった問題への対処は,効果的なCHD予防に不可欠である.
関連する概念動画
Cholesterol: Significance and Regulation
2.0K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.0K
Atherosclerosis I: Introduction
2.2K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.2K
Coronary Artery Disease I: Introduction
1.7K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Coronary Artery Disease II: Pathophysiology
1.0K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.0K
Coronary Artery Disease IV: Preventive Measures
879
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
879
Pharmacogenomics: Identification of New Drug Targets
94
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94


